ClinicalTrials.gg
Active, not recruitingNCT02570542Updated Nov 4, 2026

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

A Phase 2 interventional study of leukapheresis and Plerixafor in Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL) and Refractory Diffuse Large B-cell Lymphoma (DLBCL), sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

How we know

Updated Nov 4, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies testing carmustine in Lymphoma, Large B-Cell, Diffuse — 1 open to participants now, 2 under way, none of them phase 3. Carmustine · Lymphoma, Large B-Cell, Diffuse.

Enrollment
11th of 20
59 · median 60
Started
2015
with 1 other
Phase 2
11 of 20
1 open now
Registered
17th of 20
by date

Among the 20 studies testing carmustine in Lymphoma, Large B-Cell, Diffuse, this one is the 11th largest by enrollment, is one of 2 that started in 2015, is one of 11 in phase 2, and was the 17th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

1 of the 20 studies testing carmustine in Lymphoma, Large B-Cell, Diffuse is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About carmustine

Carmustine: first FDA approval 1977 (BICNU), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing carmustine in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

The purpose of this study is to study the impact of stem cell dose on outcome after autologous transplant.

Read the detailed description

Following enrollment, patients will be CD34+ stem cell mobilized at the discretion of the treating attending physician with the plerixafor for the achievement of >6 x10\^6 CD34+ cells/kg. The patients that fail to mobilize >6 x10\^6 CD34+ cells/kg will not be randomized and will subsequently be followed for disease progression and overall survival.. Patients with >6 x10\^6 CD34+ cells/kg cryopreserved on study will be admitted to the hospital for planned ASCT. Patients will be randomly infused with either 3-4 x 10\^6 CD34+ stem cells/kg or 6-8 x10\^6 CD34+ stem cells/kg on d0 per study randomization. The cell dose ranges within the two groups allows variability within aliquots of cells at the time of cryopreservation. Patients will receive standard supportive measures (including: growth factor support post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and treatment for neutropenic fever) as per institutional guideline practices.

03

Conditions studied

  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Relapsed Diffuse Large B-cell Lymphoma (DLBCL)
  • Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Keywords

  • CD34+ Cell Dose
  • Autologous Stem Cell Transplantation
  • 15-193
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old
  • Diagnosed with de novo DLBCL or follicular lymphoma transformed to DLBCL to one previous line of anthracycline-containing chemotherapy
  • ≥ 70
  • Complete or partial response by IWG Working Group or ICML Criteria to maximum of one salvage without pre-HDT/ salvage radiotherapy.
  • Eligible for high-dose therapy and autologous stem-cell rescue

    • Serum creatinine ≤ 1.5 mg/dL, or if creatinine >1.5 mg/dL, calculated of ≥50 mL/min by 24 hour creatinine clearance or .
    • Last cycle of most recent salvage therapy within 8 weeks of enrollment
  • Total \< 2.0 mg/dL

    o If Gilbert"s disease is suspected and total bilirubin > 2.0 mg/dL, direct bilirubin must be \< 2.0 mg/dL

  • Females of and males must agree to use an acceptable form of per institutional practices.

Exclusion criteria

Exclusion Criteria:

  • Disease progression by IWG Working Group or ICML Criteria since last therapy
  • Prior or allogeneic stem cell transplantation
  • infection
  • Comorbid condition(s) which, in the opinion of the attending physician and/or MSKCC Principal Investigator, will preclude stem cell mobilization and/or high-dose therapy with autologous stem cell rescue
  • Treatment plan that includes post-transplant maintenance therapy
  • Salvage therapy that includes involved field radiotherapy
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Active comparator
    3-4 x 10^6 CD34+ stem cells/kg

    Patients will receive standard supportive measures (including: growth factor support post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and treatment for neutropenic fever) as per institutional guideline practices.

    Procedure: leukapheresis · Drug: Plerixafor · Drug: carmustine, etoposide, cytarabine, melphalan · Procedure: Autologous Stem Cell Transplantation

  • Experimental
    6-8 x10^6 CD34+ stem cells/kg

    Patients will receive standard supportive measures (including: growth factor support post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and treatment for neutropenic fever) as per institutional guideline practices.

    Procedure: leukapheresis · Drug: Plerixafor · Drug: carmustine, etoposide, cytarabine, melphalan · Procedure: Autologous Stem Cell Transplantation

Interventions

  • Procedureleukapheresis
  • Following enrollment, patients will be CD34+ stem cell mobilized at the discretion of the treating attending physician with the plerixafor for a maximum of 4 apheresis days, for the achievement of ≥ 7 x106 CD34+ cells/kg.

  • Drugcarmustine, etoposide, cytarabine, melphalan

    Drug pages: CarmustineStudies of CarmustineCarmustine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · EtoposideStudies of EtoposideEtoposide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CytarabineStudies of CytarabineCytarabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MelphalanStudies of MelphalanMelphalan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Carmustine 300 mg/m2 day -6 Etoposide 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Cytarabine 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Melphalan 140 mg/m2 day -1 BEAM dosages may be adjusted per institutional dose adjustments based on body weight.

    Also known as: BEAM chemotherapy

  • ProcedureAutologous Stem Cell Transplantation
06

What researchers measure

Primary outcomes

  1. progression-free survival (PFS)

    equals date of progression/death - date of Autologous Stem Cell Transplantation

    Time frame: at +/- 2 weeks

Secondary outcomes

  1. the impact of CD34+ cell dose on lymphocyte subset recovery

    (ALC15) post HDT-ASCT Accordingly, each subject will be classified as a responder (i.e., recovery) or non-responder.

    Time frame: day 15

07

Study locations

14 sites
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2015 (actual). Primary completion is estimated for Oct 2027, 144 months after the start.

Of 211 non-industry phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 144 months is above that.

Counting every sponsor, half of 264 studies reached it within 52 months; a quarter within 35 and three quarters within 85.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Oct 2026 → Oct 2027 and completion Oct 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2015
First posted
Oct 7, 2015
StartActual
Oct 2015
Primary completionEst.
Oct 2027was Oct 2026
CompletionEst.
Oct 2027was Oct 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Oct 2027
Nov 4, 2026
Study completion
Oct 2026→Oct 2027
Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    Primary completion Oct 2026→Oct 2027
    Study completion Oct 2026→Oct 2027
    + 1 other change: verification date
  2. Oct 30, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02570542
Responsible party
Sponsor
First posted
Oct 7, 2015
Start date
Oct 2015
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Sergio Giralt, MD
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Plerixafor · Carmustine · Etoposide · Cytarabine · Melphalan

Start the discussion